Skip to main content

Research Repository

Advanced Search

C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?

Ho-Yen, Colan M.; Green, Andrew R.; Brentnall, Adam R.; Rakha, Emad A.; Ellis, Ian O.; Kermorgant, Stephanie; Jones, J. L.

Authors

Colan M. Ho-Yen

Adam R. Brentnall

EMAD RAKHA Emad.Rakha@nottingham.ac.uk
Professor of Breast Cancer Pathology

Stephanie Kermorgant

J. L. Jones



Abstract

BACKGROUND

Basal?like (BL) breast cancer is an aggressive form of breast cancer with limited treatment options. Recent work has identified BL breast cancer as a biologically distinct form of triple?negative breast cancer, with a worse outlook. The receptor tyrosine kinase c?Met is a novel therapeutic target associated with reduced survival in breast cancer. Few studies have specifically addressed the association between c?Met and molecular subtype of breast cancer, yet this is a key consideration when selecting patients for clinical trials. The aim of this study is to evaluate c?Met expression in a large cohort of invasive breast cancers and in particular, its correlation with molecular subtype.

METHODS

Immunohistochemistry for c?Met was performed and evaluated on 1274 invasive breast cancers using tissue microarray technology. The c?Met scores were correlated with molecular subtype, survival, and other standard clinicopathological prognostic factors.
RESULTS

Multivariate logistic regression showed c?Met was independently associated with BL status (odds ratio?=?6.44, 95% confidence interval?=?1.74?23.78, P?=?.005). There was a positive correlation between c?Met and Her2 (P?=?.005) and an inverse correlation with tumor size (P?[less than]?.001). C?Met was an independent poor prognostic factor at Cox regression analysis in all subtypes (hazard ratio?=?1.85, 95% confidence interval?=?1.07?3.19, P?=?.027) and there was a trend toward reduced survival in BL tumors overexpressing c?Met, but this was not significant.

CONCLUSIONS

C?Met is independently associated with BL breast cancer. In the future, patients with BL tumors should be included in clinical trials of anti?c?Met therapy.

Citation

Ho-Yen, C. M., Green, A. R., Brentnall, A. R., Rakha, E. A., Ellis, I. O., Kermorgant, S., & Jones, J. L. (2014). C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?. Cancer, 120(2), 163-171. doi:10.1002/cncr.28386

Journal Article Type Article
Acceptance Date Aug 20, 2013
Online Publication Date Oct 21, 2013
Publication Date Jan 15, 2014
Deposit Date Oct 17, 2018
Journal Cancer
Print ISSN 0008-543X
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 120
Issue 2
Pages 163-171
DOI https://doi.org/10.1002/cncr.28386
Public URL https://nottingham-repository.worktribe.com/output/1172720
Publisher URL https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.28386